Screening and prevention of hepatitis C virus reactivation during chemotherapy
In conclusion, HCV reactivation occurs in approximately one-fourth of HCV-infected cancer patients receiving chemotherapy. An HCV-related hepatitis flare during chemotherapy may lead to the discontinuation of potentially life-saving chemotherapy. Currently, universal HCV screening is recommended in hematological malignancy patients before chemotherapy, but there is no evidence-based guideline for other cancer patients. DAAs treatment can cure HCV infection and prevent HCV reactivation during chemotherapy.PMID:34497443 | PMC:PMC8384748 | DOI:10.3748/wjg.v27.i31.5181
Source: World Journal of Gastroenterology : WJG - Category: Gastroenterology Authors: Yuan-Rung Li Tsung-Hui Hu Wen-Chi Chen Ping-I Hsu Hui-Chun Chen Source Type: research
More News: Cancer | Cancer & Oncology | Chemotherapy | Gastroenterology | Hematology | Hepatitis | Hepatitis C